Literature DB >> 26744468

Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis.

Bo Kong1, Yan Zhu2, Guodong Li3, Jessica A Williams4, Kyle Buckley1, Ossama Tawfik5, James P Luyendyk6, Grace L Guo7.   

Abstract

Farnesoid X receptor (FXR) belongs to the nuclear receptor superfamily with its endogenous ligands bile acids. Mice with whole body FXR deficiency develop liver tumors spontaneously, but the underlying mechanism is unclear. Moreover, it is unknown whether FXR deficiency in liver alone serves as a tumor initiator or promoter during liver carcinogenesis. This study aims to evaluate the effects of hepatocyte-specific FXR deficiency (FXR(hep-/-)) in liver tumor formation. The results showed that FXR(hep-/-) mice did not show spontaneous liver tumorigenesis with aging (up to 24 mo of age). Therefore FXR(hep-/-) mice were fed a bile acid (cholic acid)-containing diet alone or along with a liver tumor initiator, diethylnitrosamine (DEN). Thirty weeks later, no tumors were found in wild-type or FXR(hep-/-) mice without any treatment or with DEN only. However, with cholic acid, while only some wild-type mice developed tumors, all FXR(hep-/-) mice presented with severe liver injury and tumors. Interestingly, FXR(hep-/-) mouse livers increased basal expression of tumor suppressor p53 protein, apoptosis, and decreased basal cyclin D1 expression, which may prevent tumor development in FXR(hep-/-) mice. However, cholic acid feeding reversed these effects in FXR(hep-/-) mice, which is associated with an increased cyclin D1 and decreased cell cycle inhibitors. More in-depth analysis indicates that the increased in cell growth might result from disturbance of the MAPK and JAK/Stat3 signaling pathways. In conclusion, this study shows that hepatic FXR deficiency may only serve as a tumor initiator, and increased bile acids is required for tumor formation likely by promoting cell proliferation.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  HCC; bile acids; tissue specific FXR

Mesh:

Substances:

Year:  2016        PMID: 26744468      PMCID: PMC4773826          DOI: 10.1152/ajpgi.00134.2015

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  33 in total

1.  Validating Stat3 in cancer therapy.

Authors:  James E Darnell
Journal:  Nat Med       Date:  2005-06       Impact factor: 53.440

2.  Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis.

Authors:  D Qiao; E D Stratagouleas; J D Martinez
Journal:  Carcinogenesis       Date:  2001-01       Impact factor: 4.944

3.  Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice.

Authors:  Prachi Borude; Genea Edwards; Chad Walesky; Feng Li; Xiaochao Ma; Bo Kong; Grace L Guo; Udayan Apte
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

4.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.

Authors:  H Wang; J Chen; K Hollister; L C Sowers; B M Forman
Journal:  Mol Cell       Date:  1999-05       Impact factor: 17.970

5.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.

Authors:  Insook Kim; Keiichirou Morimura; Yatrik Shah; Qian Yang; Jerrold M Ward; Frank J Gonzalez
Journal:  Carcinogenesis       Date:  2006-12-20       Impact factor: 4.944

6.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

7.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

Review 8.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

9.  Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.

Authors:  Guodong Li; Bo Kong; Yan Zhu; Le Zhan; Jessica A Williams; Ossama Tawfik; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2013-06-26       Impact factor: 4.219

10.  Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Meihua Wang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

View more
  17 in total

1.  FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice.

Authors:  Min Zhang; Bo Kong; Mingxing Huang; Ruixuan Wan; Laura E Armstrong; Justin D Schumacher; Daniel Rizzolo; Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Dig Liver Dis       Date:  2018-04-23       Impact factor: 4.088

2.  Chronic activation of FXR-induced liver growth with tissue-specific targeting Cyclin D1.

Authors:  Weibin Wu; Qing Wu; Xinmei Liu
Journal:  Cell Cycle       Date:  2019-06-25       Impact factor: 4.534

Review 3.  A Change in Bile Flow: Looking Beyond Transporter Inhibition in the Development of Drug-induced Cholestasis.

Authors:  Brandy Garzel; Lei Zhang; Shiew-Mei Huang; Hongbing Wang
Journal:  Curr Drug Metab       Date:  2019       Impact factor: 3.731

4.  Pleiotropic roles of FXR in liver and colorectal cancers.

Authors:  Xiongfei Huang; Mingjie Fan; Wendong Huang
Journal:  Mol Cell Endocrinol       Date:  2022-01-04       Impact factor: 4.102

5.  Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation.

Authors:  Lili Sheng; Prasant Kumar Jena; Ying Hu; Hui-Xin Liu; Nidhi Nagar; Karen M Kalanetra; Samuel William French; Samuel Wheeler French; David A Mills; Yu-Jui Yvonne Wan
Journal:  J Pathol       Date:  2017-11-01       Impact factor: 7.996

Review 6.  Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.

Authors:  Wei Jia; Guoxiang Xie; Weiping Jia
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-10-11       Impact factor: 46.802

Review 7.  The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.

Authors:  Lulu Sun; Jie Cai; Frank J Gonzalez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

8.  New mechanistic insights into hepatoprotective activity of milk thistle and chicory quantified extract: The role of hepatic Farnesoid-X activated receptors.

Authors:  Azadeh Khalili; Parviz Fallah; Seyed Ali Hashemi; Mohammad Mahdi Ahmadian-Attari; Vahid Jamshidi; Roham Mazloom; Leila Beikzadeh; Gholamreza Bayat
Journal:  Avicenna J Phytomed       Date:  2021 Jul-Aug

Review 9.  Bile acids in glucose metabolism in health and disease.

Authors:  Hagit Shapiro; Aleksandra A Kolodziejczyk; Daniel Halstuch; Eran Elinav
Journal:  J Exp Med       Date:  2018-01-16       Impact factor: 14.307

Review 10.  Effect of different bile acids on the intestine through enterohepatic circulation based on FXR.

Authors:  Junwei Xiang; Zhengyan Zhang; Hongyi Xie; Chengcheng Zhang; Yan Bai; Hua Cao; Qishi Che; Jiao Guo; Zhengquan Su
Journal:  Gut Microbes       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.